Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Functional activation of Gαq/11 protein via α1 -adrenoceptor in rat cerebral cortical membranes.

Odagaki Y, Kinoshita M, Ota T.

Clin Exp Pharmacol Physiol. 2019 Jun;46(6):567-574. doi: 10.1111/1440-1681.13084. Epub 2019 Apr 7.

PMID:
30869808
2.

Optimization and pharmacological characterization of receptor-mediated Gi/o activation in postmortem human prefrontal cortex.

Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, García-Sevilla JA.

Basic Clin Pharmacol Toxicol. 2019 Jun;124(6):649-659. doi: 10.1111/bcpt.13183. Epub 2019 Jan 4.

PMID:
30507034
3.

Receptor⁻Receptor Interactions in Multiple 5-HT1A Heteroreceptor Complexes in Raphe-Hippocampal 5-HT Transmission and Their Relevance for Depression and Its Treatment.

Borroto-Escuela DO, Narváez M, Ambrogini P, Ferraro L, Brito I, Romero-Fernandez W, Andrade-Talavera Y, Flores-Burgess A, Millon C, Gago B, Narvaez JA, Odagaki Y, Palkovits M, Diaz-Cabiale Z, Fuxe K.

Molecules. 2018 Jun 3;23(6). pii: E1341. doi: 10.3390/molecules23061341. Review.

4.

Functional coupling between adenosine A1 receptors and G-proteins in rat and postmortem human brain membranes determined with conventional guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding or [35S]GTPγS/immunoprecipitation assay.

Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Matsuoka I, García-Sevilla JA.

Purinergic Signal. 2018 Jun;14(2):177-190. doi: 10.1007/s11302-018-9603-x. Epub 2018 Feb 28.

5.

Disturbances in the FGFR1-5-HT1A Heteroreceptor Complexes in the Raphe-Hippocampal 5-HT System Develop in a Genetic Rat Model of Depression.

Borroto-Escuela DO, DuPont CM, Li X, Savelli D, Lattanzi D, Srivastava I, Narváez M, Di Palma M, Barbieri E, Andrade-Talavera Y, Cuppini R, Odagaki Y, Palkovits M, Ambrogini P, Lindskog M, Fuxe K.

Front Cell Neurosci. 2017 Oct 10;11:309. doi: 10.3389/fncel.2017.00309. eCollection 2017.

6.

Functional activation of Gαq coupled to 5-HT2A receptor and M1 muscarinic acetylcholine receptor in postmortem human cortical membranes.

Odagaki Y, Kinoshita M, Ota T, Javier Meana J, Callado LF, García-Sevilla JA.

J Neural Transm (Vienna). 2017 Sep;124(9):1123-1133. doi: 10.1007/s00702-017-1749-0. Epub 2017 Jul 7.

PMID:
28687907
7.

A Case of Persistent Generalized Retrograde Autobiographical Amnesia Subsequent to the Great East Japan Earthquake in 2011.

Odagaki Y.

Case Rep Psychiatry. 2017;2017:5173605. doi: 10.1155/2017/5173605. Epub 2017 Mar 1.

8.

Comparative analysis of pharmacological properties of xanomeline and N-desmethylclozapine in rat brain membranes.

Odagaki Y, Kinoshita M, Ota T.

J Psychopharmacol. 2016 Sep;30(9):896-912. doi: 10.1177/0269881116658989. Epub 2016 Jul 27.

PMID:
27464743
9.

Is scintigraphy necessary to detect migration of 125I seeds after brachytherapy for early prostate cancer?

Odagaki Y, Ohori M, Yoshimura M, Nakshima J, Ohno Y, Mikami R, Nakayama H, Tokuuye K, Tachibana M.

Int J Clin Oncol. 2016 Apr;21(2):397-401. doi: 10.1007/s10147-015-0901-9. Epub 2015 Sep 22.

PMID:
26394786
10.

Adenosine A1( )receptors are selectively coupled to Gα(i-3) in postmortem human brain cortex: Guanosine-5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTPγS) binding/immunoprecipitation study.

Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, García-Sevilla JA.

Eur J Pharmacol. 2015 Oct 5;764:592-8. doi: 10.1016/j.ejphar.2015.07.049. Epub 2015 Jul 23.

PMID:
26213104
11.

Functional activation of G-proteins coupled with muscarinic acetylcholine receptors in rat brain membranes.

Odagaki Y, Kinoshita M, Toyoshima R.

J Pharmacol Sci. 2014;125(2):157-68. Epub 2014 May 20.

13.
14.

Pharmacological characterization of M1 muscarinic acetylcholine receptor-mediated Gq activation in rat cerebral cortical and hippocampal membranes.

Odagaki Y, Kinoshita M, Toyoshima R.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Nov;386(11):937-47. doi: 10.1007/s00210-013-0887-7. Epub 2013 Jun 9.

PMID:
23748234
15.

Primary large cell neuroendocrine carcinoma of the ureter.

Oshiro H, Odagaki Y, Iobe H, Ozu C, Takizawa I, Nagai T, Matsubayashi J, Inagaki A, Miyake S, Nagao T.

Int J Clin Exp Pathol. 2013;6(4):729-36. Epub 2013 Mar 15.

16.

Group II metabotropic glutamate receptor-mediated activation of G-proteins in rat hippocampal and striatal membranes.

Odagaki Y, Kinoshita M, Toyoshima R.

Neurosci Lett. 2013 Feb 28;539:22-6. doi: 10.1016/j.neulet.2013.01.033. Epub 2013 Feb 4.

PMID:
23384570
17.
18.

Discovery of new orally active prostaglandin D2 receptor antagonists.

Iwahashi M, Naganawa A, Kinoshita A, Shimabukuro A, Nishiyama T, Ogawa S, Matsunaga Y, Tsukamoto K, Okada Y, Matsumoto R, Nambu F, Oumi R, Odagaki Y, Katagi J, Yano K, Tani K, Nakai H, Toda M.

Bioorg Med Chem. 2011 Nov 15;19(22):6935-48. doi: 10.1016/j.bmc.2011.08.065. Epub 2011 Sep 2.

PMID:
21982795
19.

Functional coupling between metabotropic glutamate receptors and G-proteins in rat cerebral cortex assessed by guanosine-5'-O-(3-[(35)S]thio)triphosphate binding assay.

Odagaki Y, Kinoshita M, Toyoshima R.

Basic Clin Pharmacol Toxicol. 2011 Sep;109(3):175-85. doi: 10.1111/j.1742-7843.2011.00705.x. Epub 2011 May 5.

20.

Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase.

Matsumoto T, Miyake K, Yamamoto S, Orimo H, Miyake N, Odagaki Y, Adachi K, Iijima O, Narisawa S, Millán JL, Fukunaga Y, Shimada T.

Hum Gene Ther. 2011 Nov;22(11):1355-64. doi: 10.1089/hum.2010.210. Epub 2011 Jun 8.

21.

Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.

Yamashita H, Yoda H, Kuroki N, Kuwabara M, Odagaki Y, Kazawa T, Toyoshima R, Maruki T.

Psychopharmacology (Berl). 2011 Jan;213(1):1-9. doi: 10.1007/s00213-010-2002-9. Epub 2010 Sep 4.

PMID:
20820759
22.
23.

Pharmacological characterization of alpha2D-adrenergic receptor-mediated [35S]GTPgammaS binding in rat cerebral cortical membranes.

Odagaki Y, Toyoshima R.

Pharmacol Res. 2008 Jun;57(6):435-44. doi: 10.1016/j.phrs.2008.04.006. Epub 2008 Apr 26.

PMID:
18515144
24.

5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes.

Odagaki Y, Toyoshima R.

Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):462-6.

PMID:
17439416
25.

Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5'-O-(gamma-thiotriphosphate) binding in rat striatal membranes.

Odagaki Y, Toyoshima R.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1304-12. Epub 2006 Jul 7.

PMID:
16824659
26.
27.

5-HT1A receptor-mediated G protein activation assessed by [35S]GTPgammaS binding in rat cerebral cortex.

Odagaki Y, Toyoshima R.

Eur J Pharmacol. 2005 Oct 3;521(1-3):49-58. Epub 2005 Sep 21.

PMID:
16182280
28.

Detailed pharmacological characterization of 5-HT1A-receptor-mediated [35S]GTP gamma S binding in rat hippocampal membranes.

Odagaki Y, Toyoshima R.

J Pharmacol Sci. 2005 May;98(1):66-76. Epub 2005 May 12. Erratum in: J Pharmacol Sci. 2005 Jun;98(2):190.

29.
30.

Lack of G protein-coupled sigma receptors in rat brain membranes: receptor-mediated high-affinity GTPase activity and [35S]GTPgammaS binding studies.

Odagaki Y, Toyoshima R, Yamauchi T.

J Neural Transm (Vienna). 2005 Jul;112(7):873-83. Epub 2004 Nov 3.

PMID:
15526140
31.

Highly potent PDE4 inhibitors with therapeutic potential.

Ochiai H, Ohtani T, Ishida A, Kusumi K, Kato M, Kohno H, Odagaki Y, Kishikawa K, Yamamoto S, Takeda H, Obata T, Nakai H, Toda M.

Bioorg Med Chem. 2004 Sep 1;12(17):4645-65.

PMID:
15358291
32.

Design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors.

Ochiai H, Odagaki Y, Ohtani T, Ishida A, Kusumi K, Kishikawa K, Yamamoto S, Takeda H, Obata T, Kobayashi K, Nakai H, Toda M.

Bioorg Med Chem. 2004 Oct 1;12(19):5063-78.

PMID:
15351390
33.
34.

Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Identification of 2-azabicyclo[4.1.0]heptan-3-imines.

Kawanaka Y, Kobayashi K, Kusuda S, Tatsumi T, Murota M, Nishiyama T, Hisaichi K, Fujii A, Hirai K, Naka M, Komeno M, Odagaki Y, Nakai H, Toda M.

Bioorg Med Chem. 2003 Apr 17;11(8):1723-43.

PMID:
12659759
35.
36.

Diastereoselective synthesis of new psi[(E)-CH=CMe]- and psi[(Z)-CH=CMe]-type alkene dipeptide isosteres by organocopper reagents and application to conformationally restricted cyclic RGD peptidomimetics.

Oishi S, Kamano T, Niida A, Odagaki Y, Hamanaka N, Yamamoto M, Ajito K, Tamamura H, Otaka A, Fujii N.

J Org Chem. 2002 Aug 23;67(17):6162-73.

PMID:
12182657
37.

Regio- and stereoselective synthesis of (E)-alkene trans-Xaa-Pro dipeptide mimetics utilizing organocopper-mediated anti-S(N)2' reactions.

Otaka A, Katagiri F, Kinoshita T, Odagaki Y, Oishi S, Tamamura H, Hamanaka N, Fujii N.

J Org Chem. 2002 Aug 23;67(17):6152-61.

PMID:
12182656
38.

Clarification of mechanism of human sputum elastase inhibition by a new inhibitor, ONO-5046, using electrospray ionization mass spectrometry.

Nakayama Y, Odagaki Y, Fujita S, Matsuoka S, Hamanaka N, Nakai H, Toda M.

Bioorg Med Chem Lett. 2002 Sep 2;12(17):2349-53.

PMID:
12161131
39.

A practical synthesis and biological evaluation of 9-halogenated PGF analogues.

Tani K, Naganawa A, Ishida A, Egashira H, Odagaki Y, Miyazaki T, Hasegawa T, Kawanaka Y, Sagawa K, Harada H, Ogawa M, Maruyama T, Nakai H, Ohuchida S, Kondo K, Toda M.

Bioorg Med Chem. 2002 Jun;10(6):1883-94.

PMID:
11937346
40.

Diastereoselective synthesis of psi[(E)-CMe=CH]- and psi[(E)-CMe=CMe]- type dipeptide isosteres based on organocopper-mediated anti-S(N)2' reaction.

Oishi S, Niida A, Kamano T, Odagaki Y, Tamamura H, Otaka A, Hamanaka N, Fujii N.

Org Lett. 2002 Apr 4;4(7):1055-8.

PMID:
11922781
41.

Diastereoselective synthesis of psi[(E)-CH=CMe]- and psi[(Z)-CH=CMe]-type dipeptide isosteres by organocopper-mediated anti-S(N)2' reaction.

Oishi S, Kamano T, Niida A, Odagaki Y, Tamamura H, Otaka A, Hamanaka N, Fujii N.

Org Lett. 2002 Apr 4;4(7):1051-4.

PMID:
11922780
42.

Development of orally active nonpeptidic inhibitors of human neutrophil elastase.

Ohmoto K, Yamamoto T, Okuma M, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M, Cheronis JC, Spruce LW, Gyorkos A, Wieczorek M.

J Med Chem. 2001 Apr 12;44(8):1268-85.

PMID:
11312926
43.

The crystal structure of the complex of non-peptidic inhibitor of human neutrophil elastase ONO-6818 and porcine pancreatic elastase.

Odagaki Y, Ohmoto K, Matsuoka S, Hamanaka N, Nakai H, Toda M, Katsuya Y.

Bioorg Med Chem. 2001 Mar;9(3):647-51.

PMID:
11310599
44.

Cyclic AMP-mediated signaling components are upregulated in the prefrontal cortex of depressed suicide victims.

Odagaki Y, García-Sevilla JA, Huguelet P, La Harpe R, Koyama T, Guimón J.

Brain Res. 2001 Apr 20;898(2):224-31.

PMID:
11306008
45.

Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity.

Tamamura H, Sugioka M, Odagaki Y, Omagari A, Kan Y, Oishi S, Nakashima H, Yamamoto N, Peiper SC, Hamanaka N, Otaka A, Fujii N.

Bioorg Med Chem Lett. 2001 Feb 12;11(3):359-62. Erratum in: Bioorg Med Chem Lett 2001 Sep 3;11(17):2409.

PMID:
11212110
47.

Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase.

Ohmoto K, Yamamoto T, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M, Cheronis JC, Spruce LW, Gyorkos A, Wieczorek M.

J Med Chem. 2000 Dec 28;43(26):4927-9. No abstract available.

PMID:
11150162
50.

Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression.

Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y, Kusumi I, Odagaki Y, Denda K, Ohmori T, Koyama T.

J Affect Disord. 2000 Dec;61(1-2):127-32.

PMID:
11099751

Supplemental Content

Loading ...
Support Center